REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail tested for Tough-to-Treat blood cancer
Disease control CompletedThis study tested a combination of three oral medications—pomalidomide, ixazomib, and dexamethasone—for adults with multiple myeloma that has come back or stopped responding to prior treatments. The goal was to see if this drug combo could control the cancer and delay its progres…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for multiple myeloma patients Who've run out of options
Disease control CompletedThis early-stage trial tested a new combination of three drugs (selinexor, carfilzomib, and dexamethasone) for patients with multiple myeloma that had returned or stopped responding to previous treatments. The main goals were to find the safest dose and understand side effects in…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New combo tested for Tough-to-Treat blood cancer
Disease control CompletedThis early-stage study aimed to find a safe dose for a new three-drug combination (ibrutinib, lenalidomide, and dexamethasone) for adults with multiple myeloma that has returned or stopped responding to prior treatments. The main goal was to check for serious side effects and det…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for patients out of options: immune therapy tested for aggressive blood cancer
Disease control CompletedThis study tested a new drug called Elranatamab for Chinese patients with a severe form of multiple myeloma that no longer responds to standard treatments. The drug is an injection that works by activating the body's own immune system to attack the cancer cells. The trial had two…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC